异基因造血干细胞移植后复发急性髓系白血病/骨髓增生异常综合征患者人类白细胞抗原丢失的危险因素与生存分析
该研究回顾性分析2010年1月至2021年6月本中心2359例清髓性异基因造血干细胞移植后复发AML/MDS患者,对179例可溯源患者行HLA基因丢失检测,HLA丢失组47例(27.2%),非HLA丢失组126例(72.8%)。多因素Cox分析显示HLA错配位点≥3、移植至复发时间≤6个月及复发时骨髓供者嵌合率(CD3)是HLA丢失复发的独立影响因素;HLA丢失组二次移植对OS有显著正面影响,而DLI未能延长OS。
要点
- HLA丢失组47例(27.2%),非HLA丢失组126例(72.8%),两组基线特征无显著差异。
- HLA错配位点≥3(HR=3.66)、移植至复发≤6个月(HR=7.92)及复发时供者嵌合率(CD3)(HR=1.02)为HLA丢失复发独立影响因素。
- HLA丢失组二次移植对OS有显著正面影响(p=0.017),但仅5例接受二次移植;DLI未能延长HLA丢失组OS(p=0.42)。
核心结论
- 移植后复发患者进行HLA丢失检测至关重要,尤其对于HLA错配位点较多及非同胞供者。
- HLA丢失检测对复发后后续治疗选择有指导作用,HLA丢失者二次移植比DLI更合适。
研究设计与样本
- 回顾性研究,收集2010年1月至2021年6月本中心清髓性异基因造血干细胞移植后复发AML/MDS患者临床资料。
- 共2359例患者入选,对179例复发患者DNA行回顾性HLA基因丢失检测,按二代测序结果分为HLA丢失组47例(27.2%)和非HLA丢失组126例(72.8%),6例因结果未确认被排除。
主要发现
- 两组基线特征无显著统计学差异,但供受者关系及HLA错配位点在两组间有统计学差异(均p<0.001)。
- 多因素Cox分析显示HLA错配位点≥3(HR=3.66;95%CI:1.61-8.31;p=0.002)、移植至复发时间≤6个月(HR=7.92;95%CI:3.35-18.74;p<0.001)及复发时骨髓供者嵌合率(CD3)(HR=1.02;95%CI:1.00-1.03;p=0.036)是影响HLA丢失复发的独立因素。
- 移植后HLA丢失复发组FLT3-ITD或CEBPA突变转阴比例显著低于非HLA丢失组(0.0% vs 45.5%,p=0.003;0.0% vs 80.0%,p=0.035),HLA丢失组中FLT3-ITD或CEBPA突变患者无一转阴。
- 非HLA丢失组复发时基因突变转阴数量显著高于HLA丢失组(p=0.001)。
- HLA丢失组使用DLI未能延长OS(p=0.42);二次移植对HLA丢失组OS有显著正面影响(p=0.017),但HLA丢失组仅5例接受二次移植。
临床怎么用
- 作者认为,移植后复发患者应进行HLA丢失检测,尤其对于HLA错配位点较多及非同胞供者。
- 作者认为,HLA丢失检测对复发后后续治疗选择有指导作用,HLA丢失者二次移植比DLI更合适。
局限性
- HLA丢失组仅5例患者接受二次移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
To investigate the clinical characteristics and risk factors of specific human leukocyte antigen loss (HLA loss) in relapsed acute myeloid leukaemia (AML)/myelodysplastic syndrome (MDS) patients after allogeneic haematopoietic stem cell transplantation (allo-HSCT), and compare the responses of patients with HLA loss relapse with those without HLA loss (non-HLA loss) to different treatment regimens. Clinical data of traceable patients with AML/MDS after myeloablative allo-HSCT in our centre between January 2010 and June 2021, who experienced disease relapse after the transplantation, were collected. The patients were divided into the HLA loss relapse group and the non-HLA loss relapsed group based on HLA loss gene test findings by next-generation sequencing. The patients' median overall survival (OS) after the relapse were compared, and univariate and multivariate analyses were performed using the Kaplan-Meier survival curve and Cox proportional hazard model to explore the responses to different treatments after relapse. A total of 2359 patients were selected. Retrospective HLA gene loss gene detection was performed for the deoxyribonucleic acid in 179 relapsed patients, including 47 patients in the HLA loss group (27.2%), 126 patients in the non-HLA loss group (72.8%) and 6 patients were excluded due to a lack of confirmed results. There was no significant statistical difference in the baseline characteristics of patients between the two groups, but as to transplantation-related characteristics, the donor-recipient relationship and HLA mismatched loci were statistically different between the two groups (both p < 0.001). Multivariate Cox analysis showed that more HLA mismatched loci ≥3 (HR = 3.66; 95% CI: 1.61-8.31; p = 0.002), time (≤6 months) from HSCT to relapse (HR = 7.92; 95% CI: 3.35-18.74; p < 0.001) and donor chimerism (CD3) in bone marrow at relapse (HR = 1.02; 95% CI: 1.00-1.03; p = 0.036) were independent factors affecting HLA loss relapse. The ratio of negative conversion of FLT3-ITD or CEBPA mutation was significantly lower in patients with post-transplantation HLA loss relapse than in the non-HLA loss group (0.0% vs. 45.5%, p = 0.003; 0.0% vs. 80.0%, p = 0.035), with none of the patients with FLT3-ITD or CEBPA mutation turned negative in the HLA loss group. The number of gene mutations turned negative when relapse in the non-HLA loss group was remarkably higher than that in the HLA loss group (p = 0.001). Using donor lymphocyte infusion (DLI) could not prolong OS for the HLA loss group (p = 0.42). Nevertheless, second transplantation had a significant positive impact on OS in the HLA loss group (p = 0.017), although only five patients in the HLA loss group underwent second transplantation. However, patients in the non-HLA loss group using DLI had a relatively longer OS time than those without DLI (p = 0.017). Second transplantation could also prolong OS in the non-HLA loss group, but the effect was not as significant as in the HLA loss group (p = 0.053). In summary, HLA loss detection is essential for patients with recurrence after transplantation, especially for those with more HLA mismatched loci and non-sibling donor. Furthermore, the detection of HLA loss has a guiding role in choosing subsequent therapy when relapsed, as secondary transplantation is more suitable than DLI for those with HLA loss.
引用
- Zhang T, Zhang Y, Zhou M, et al. Risk factors and survival analysis of human leukocyte antigen loss in relapsed acute myeloid leukaemia/myelodysplastic syndrome patients after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2024. PMID: 38327115. doi:10.1111/bjh.19304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。